Biography
Sid Roychoudhury is a Global Product General Manager (GPGM) at Amgen where he leads multiple biologics development programs in immuno-oncology, including tarlatamab (AMG 757), a half-life extended DLL3-targeting BiTE (bispecific T cell engager) molecule under investigation for the treatment of small-cell lung cancer. Prior to joining Amgen in 2015, Sid spent ~12 years in various positions of increasing responsibilities in medical affairs, project management, external innovation, and finally as a Compound Development Team Leader (CDTL) in early development within the Immunology therapeutic area. Prior to J&J, Sid spent ~ 8 years in anti-bacterial drug discovery at Procter & Gamble Pharmaceuticals and led the discovery of TAIGEXYN®, a non-fluorinated quinolone, which is approved in multiple countries for the treatment of drug-resistant infections. Sid conducted his postdoctoral research at Eli Lilly & Company and holds a PhD in microbiology & immunology from University of Illinois College of Medicine in Chicago.